Skip to main content

UTAH MEDICAL PRODUCTS INC

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

UTMD$72.86-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 15. Exhibits, Financial Statement Schedules

(a) The following documents are filed as part of this report or incorporated herein by reference.

  1. Financial Statements.

(See Table of Contents in Item 8 above.)

  1. Supplemental Schedule.

Financial Statement Schedules are omitted because they are inapplicable or the required information is otherwise included in the accompanying Financial Statements and the notes thereto.

  1. Exhibits.
Exhibit #Title of DocumentLocation
3.1Articles of Restatement of the Articles of IncorporationIncorporated by Reference (1)
3.2Articles of Correction to the Restated Articles of IncorporationIncorporated by Reference (1)
3.3BylawsIncorporated by Reference (2)
10.1Employment Agreement dated December 21, 1992 with Kevin L. Cornwell*Incorporated by Reference (3)
10.2Amendment, effective May 15, 1998, to Employment Agreement dated December 21, 1992 with Kevin L. Cornwell*Incorporated by Reference (3)
10.3Utah Medical Products, Inc. 2013 Employees’ and Directors’ Incentive Plan*Incorporated by Reference (4)
10.4Utah Medical Products, Inc., 2023 Employees’ and Directors’ Incentive Plan*Incorporated by Reference (5)
19.1Insider Trading PolicyIncorporated by Reference (6)
21.1Subsidiaries of Utah Medical Products, Inc.This filing
23.1Consent of Haynie & Company, UTMD’s independent auditors for the years ended December 31, 2025 and December 31, 2024This filing
23.2Consent of Nortons Assurance Limited, Femcare Group Limited’s independent auditors for the years ended December 31, 2025 and December 31, 2024This filing
31.1Certification of CEO pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002This Filing
31.2Certification of Principal Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002This Filing
32.1Certification of CEO pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002This Filing
32.2Certification of Principal Financial Officer pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002This Filing
97.1Policy Relating to Recovery of Erroneously Awarded CompensationIncorporated by Reference (6)
101.insXBRL Instance DocumentThis Filing
101.xsdXBRL Taxonomy Extension Schema DocumentThis Filing
101.calXBRL Taxonomy Extension Calculation Linkbase DocumentThis Filing
101.defXBRL Taxonomy Extension Definition Linkbase DocumentThis Filing
101.tabXBRL Taxonomy Extension Label Linkbase DocumentThis Filing
101.preXBRL Taxonomy Extension Presentation Linkbase DocumentThis Filing
  • Management contract of compensatory plan or arrangement required to be filed pursuant to Item 14(c).

(1)Incorporated by reference from the Company’s annual report on form 10-K filed with the Commission for the year ended December 31, 2004.

(2)Incorporated by reference from the Company’s report on form 8-K filed with the Commission on February 13, 2014.

(3)Incorporated by reference from the Company’s annual report on form 10-K filed with the Commission for the year ended December 31, 2003.

(4)Incorporated by reference from the Company’s 2013 definitive proxy statement on form DEF 14A filed with the Commission on March 7, 2013.

(5)Incorporated by reference from the Company’s report on form S-8 filed with the Commission on July 14, 2023.

(6)Incorporated by reference from the Company’s annual report on form 10-K filed with the Commission for the year ended December 31, 2024.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.